INT351537

From wiki-pain
Revision as of 17:31, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 1.44
Pain Relevance 0.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Prom1) plasma membrane (Prom1) cilium (Prom1)
Anatomy Link Frequency
arm 2
Prom1 (Mus musculus)
Pain Link Frequency Relevance Heat
imagery 96 97.84 Very High Very High Very High
anesthesia 3 5.00 Very Low Very Low Very Low
Glutamate 3 5.00 Very Low Very Low Very Low
isoflurane 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Malignant Neoplastic Disease 9 99.28 Very High Very High Very High
Cancer 240 96.60 Very High Very High Very High
Glioma 12 95.00 High High
Glioblastoma 30 64.96 Quite High
Colon Cancer 9 61.28 Quite High
Hypoxia 6 52.08 Quite High
Metastasis 6 5.00 Very Low Very Low Very Low
Dislocations 6 5.00 Very Low Very Low Very Low
Skin Cancer 6 5.00 Very Low Very Low Very Low
Recurrence 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In order to test whether the AC133.1 antibody could detect CD133 expression in vivo, CD133-overexpressing and wild-type U251 cells were subcutaneously (s.c.) implanted into nude mice (for a tumor growth curve, see Figure S1).
Regulation (detect) of CD133-overexpressing associated with cancer
1) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.47 Pain Relevance 0.08
If targeting CD133 (AC133) should not prove specific enough for the detection of CSCs in situ [40], possible solutions might include the identification of more specific CSC-targets or the production of dual specificity recombinant antibodies, i.e., with one arm specific for CD133 and the other for another CSC-antigen.
Regulation (targeting) of CD133 in arm
2) Confidence 0.25 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.48 Pain Relevance 0.04
If targeting CD133 (AC133) should not prove specific enough for the detection of CSCs in situ [40], possible solutions might include the identification of more specific CSC-targets or the production of dual specificity recombinant antibodies, i.e., with one arm specific for CD133 and the other for another CSC-antigen.
Regulation (targeting) of AC133 in arm
3) Confidence 0.25 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.48 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox